TABLE 3.

Biodistribution of ¹¹¹In-IL-M1₍₅₀₎ (at 24 and 48 h after injection) in nude mice bearing both epithelioid (M28) and sarcomatoid (VAMT-1) subtypes of mesothelioma tumors (n=4). A control study performed using non-targeted ¹¹¹In-CL is also shown (n=3). Data are %ID/g ± SD.

Organ	111In-IL-M1(50)		Control 111In-CL
	24 h	48 h	48 h
Liver	15.69±2.28	7.97±0.34	10.23±0.11
Heart	0.57±0.13	0.19±0.13	0.31±0.11
Kidney	2.26±1.24	1.17±2.75	1.40±0.51
Lung	0.72±0.33	0.55±0.24	0.55±0.29
Spleen	8.87±0.91	4.06.±086	5.04±0.89
Pancreas	0.48±0.18	0.21±0.23	0.20±0.56
Stomach	0.12±0.78	0.69±0.68	0.45±0.66
Sm. Int.	0.74±0.89	0.41±0.98	0.47±0.91
Ig. Int.	0.71±0.92	0.72±0.91	0.41±0.93
Muscle	0.14±0.02	0.09±0.05	0.07±0.01
Fat	0.23±0.01	0.21±0.03	0.10±0.02
Blood	0.53±0.21	0.13±0.63	0.50±0.58
Tumor (M28)	3.24±0.24	4.01±0.39	0.97±0.48
Tumor (VAMT-1)	3.86±0.23	4.69±0.72	0.40±0.42